Research programme: infertility therapeutics - Merck Sharp and DohmeAlternative Names: ORG 214444; ORG 241549; ORG 33409
Latest Information Update: 23 Feb 2015
At a glance
- Originator Organon
- Developer Merck & Co
- Class Dihydropyridines; Follicle stimulating hormones; Gonadotropins; Recombinant proteins
- Mechanism of Action Ovarian follicle stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Female infertility